ZURA
Zura Bio Limited
$4.27
+0.71
(+19.94%)
Mkt Cap
334.44M
Volume
5,039,426
52W Range
3.25-7.44
Sector
Healthcare
Beta
-0.04
EPS (TTM)
-1.13 USD
P/E Ratio
-4.94
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Net Income | (68.65M) | (52.40M) | (60.36M) | (25.74M) | 8.42M |
| EPS | -1.06 | -0.60 | -2.09 | 0.21 | 0.40 |
| Free Cash Flow | (64.93M) | (28.15M) | (23.05M) | (13.20M) | (1.10M) |
| FCF / Share | -0.69 | -0.37 | -0.70 | -0.77 | -0.06 |
| Operating CF | (64.81M) | (28.08M) | (15.05M) | (1.20M) | (1.10M) |
| Total Assets | 113.95M | 179.53M | 100.84M | 5.26M | 140.55M |
| Total Debt | 0 | 0 | 0 | 7.76M | 0 |
| Cash & Equiv | 109.41M | 176.50M | 99.81M | 1.57M | 729,223 |
| Book Value | 101.54M | 146.81M | 59.33M | (32.06M) | 130.20M |
| Return on Equity | -0.68 | -0.36 | -1.02 | N/A | 0.06 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.30M) | (24.22M) | (17.18M) | (18.04M) | (15.99M) | (17.44M) | (9.05M) | (20.70M) | (10.33M) | (7.75M) | (8.47M) | (8.27M) |
| EPS | -0.21 | -0.22 | -0.49 | -0.21 | -0.17 | -0.19 | -0.14 | -0.26 | -0.17 | -0.02 | -0.18 | -0.18 |
| Free Cash Flow | (20.93M) | (18.94M) | (22.30M) | (15.48M) | (16.05M) | (11.11M) | (10.87M) | (5.67M) | (6.63M) | (9.99M) | (4.05M) | (4.82M) |
| FCF / Share | -0.17 | -0.17 | -0.24 | -0.16 | -0.17 | -0.17 | -0.17 | -0.06 | -0.09 | -0.21 | -0.09 | -0.10 |
| Operating CF | (20.90M) | (18.92M) | (22.28M) | (15.44M) | (16.03M) | (11.06M) | (10.82M) | (5.65M) | (6.62M) | (4.98M) | (4.05M) | (2.57M) |
| Total Assets | 213.40M | 228.64M | 113.95M | 143.94M | 157.81M | 172.50M | 179.53M | 189.07M | 189.50M | 90.48M | 100.84M | 104.59M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 205.13M | 225.59M | 109.41M | 139.02M | 154.49M | 170.57M | 176.50M | 188.22M | 188.44M | 89.82M | 99.81M | 103.86M |
| Book Value | 197.09M | 216.90M | 101.54M | 108.24M | 125.91M | 138.20M | 146.81M | 153.05M | 156.52M | 61.01M | 59.33M | 63.21M |
| Return on Equity | -0.13 | -0.11 | -0.17 | -0.17 | -0.13 | -0.13 | -0.06 | -0.14 | -0.07 | -0.13 | -0.14 | -0.13 |
ZURA News
Zura Bio to Participate in the Cantor Global Healthcare Conference
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Target Price from Brokerages
Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Here’s Why
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)